There are currently three iron chelation drugs available. (This will change, as more drugs are introduced).
1) Deferoxamine (Desferal). Given as a subcutaneous infusion. Given by IV when high iron load is significantly affecting heart function.
2) Deferiprone. (L1, Ferriprox, Kelfer). Taken as an oral medication 3 times daily at a dose of 75 mg/kg. Has been shown to be the most effective chelator for cardiac iron and also has a cardioprotective effect. Not as effective as desferal in the liver, but does control liver iron concentrations at acceptable levels.
3) Deferasirox. (Exjade, Asunra, Desirox). Taken orally. Novartis recommends it once daily. 30 mg/kg daily. (Recent studies have shown a dose of 32.6 mg/kg daily, effectively maintains low ferritin levels). For high ferritin levels, a dose of 40 mg/kg is required, if tolerated. If not, a different chelation drug or combination should be considered. Notes for starting on any of the deferasirox drugs: Do not start out at 30 mg/kg. Start at 10-15 mg/kg daily, so that the body becomes accustomed to the drug. This reduces the incidence of the common rash and also allows the stomach time to adjust to the new med. After 2 weeks, try raising the dose. If no side effects are seen, keep the dose at the prescribed amount. Deferasirox alone, may not be the best choice for high ferritin patients. Ongoing informal trials by members of thalpal have shown that splitting the dose into two, taking half in morning and half later in the day, make deferasirox more tolerable and also more effective. Parents have been pleased with the progress their children are making when they split the dose. Also, after more testing, Novartis has expanded the list, so a variety of juices and soft foods are acceptable for mixing purposes.
Patience is often needed when using deferasirox. Many patients with high iron show little to no progress in ferritin levels during their first year on deferasirox. However, in most of these cases, substantial progress will be noted in the second year. Many make the mistake of giving up too early. If a higher iron load exists in the organs, it will take some time to reverse, but the drug does work for most patients, as long as they are fully compliant. 40 mg/kg may be required.
The most effective chelation method currently known is a combination of desferal and deferiprone. This is the quickest way to reduce iron loads and to clean iron from the organs. The dosages will depend on the individual's iron load, as measured by T2* and MRI. For patients with high iron loads, this combination gets the highest rating.
There have been small trials involving desferal and deferasirox. These trials have had positive results. Patients experienced a drop in iron loads, when using only one chelator could not reduce the ferritin level to acceptable ranges. Currently a ferritin of 500 is considered an acceptable load. If frequent monitoring is available, ferritins in the 100-300 range are reasonable goals. No new side effects have been seen with this combination. It should be considered in patients whose iron load is not under control, using one of the drugs alone.
Deferasirox and deferiprone have been in small trials together for short periods. While it appears that it may be an effective combination, not enough is known about long term effects on the kidneys and liver to recommend this at this time.
When heart function is greatly reduced and cardiac failure is likely, the patient should be put on IV desferal 24/7.
What is best? That depends on the patient. Many patients will not stay compliant with desferal, and the oral chelators prove a valuable substitute. When it comes to chelation in the real world where patients are often less than fully compliant, a "whatever works" philosophy may be needed. Being flexible and innovative in establishing good compliance routines may be needed for some patients. In the end, this may determine whether a patient lives or dies. Most authorities believe that patients should not be on just one chelator during their lifetimes, as switching helps to minimize the long term side effects of the drugs. For those counseling thals about compliance, flexibility is necessary. Stubborn insistence on a specific chelator when the patient will not comply has led to the deaths of many thalassemics.
* All chelators have known side effects, which can be seen by searching for that particular drug online. When a drug is unsuitable for that patient, another chelator must be used.